Unicycive Therapeutics CEO - What is Hypophosphatemia?

Описание: For the full presentation and in-depth analysis, watch the complete video at https://channelchek.cc/44cWmZt

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

Noble Capital Markets Emerging Growth Virtual Healthcare Conference
Research Analyst: Robert Leboyer
Unicycive Therapeutics CEO - Shalabh Gupta, M.D.